Also from this source

You just read:

Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome

News provided by

Telik, Inc.

Sep 29, 2011, 09:00 ET